Patent ID: 11897954
Assignee: NATIONAL CANCER CENTER
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 8:
9. The bispecific antibody according to claim 2, wherein the heavy chain variable region of the anti-CD3 antibody comprises a CDR1 consisting of amino acids 31 to 35 of SEQ ID NO: 14, a CDR2 consisting of amino acids 50 to 68 of SEQ ID NO: 14, and a CDR3 consisting of amino acids 101 to 114 of SEQ ID NO: 14, and the light chain variable region of the anti-CD3 antibody comprises a CDR1 consisting of amino acids 168 to 181 of SEQ ID NO: 14, a CDR2 consisting of amino acids 197 to 203 of SEQ ID NO: 14, and a CDR3 consisting of amino acids 236 to 244 of SEQ ID NO: 14.